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Abstract
Introduction
The evidence on the relationship between breast cancer and different types of antihyperten-
sive drugs taken for at least 5 years is limited and inconsistent. Furthermore, the debate
has recently been fueled again with new data reporting an increased risk of breast
cancer among women with a long history of use of antihypertensive drugs compared with
nonusers.
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Methods
In this case-control study, we report the antihypertensive drugs–breast cancer relationship
in 1,736 breast cancer cases and 1,895 healthy controls; results are reported stratifying by
the women’s characteristics (i.e., menopausal status or body mass index category) tumor
characteristics and length of use of antihypertensive drugs.
Results
The relationship among breast cancer and use of calcium channel blockers (CCB) for
5 or more years had odds ratio (OR) = 1.77 (95% CI, 0.99 to 3.17). Stratifying by BMI, the
OR increased significantly in the group with BMI 25 (OR 2.54, 95% CI, 1.24 to 5.22).
CCBs were even more strongly associated with more aggressive tumors, (OR for invasive
tumors = 1.96, 95% CI = 1.09 to 3.53; OR for non ductal cancers = 3.97, 95% CI = 1.73 to
9.05; OR for Erbb2+ cancer = 2.97, 95% CI: 1.20 to 7.32). On the other hand, premeno-
pausal women were the only group in which angiotensin II receptor blockers may be associ-
ated with breast cancer (OR = 4.27, 95% CI = 1.32 to 13.84) but this could not be identified
with any type or stage. Use of angiotensin-converting-enzyme inhibitors, beta blockers and
diuretics were not associated with risk.
Conclusions
In this large population-based study we found that long term use of calcium channel block-
ers is associated with some subtypes of breast cancer (and with breast cancer in over-
weight women).
Introduction
Hypertension is a highly prevalent disease affecting around 30–45% of the general population
[1] and antihypertensive medications are among the most commonly prescribed medications.
According to the latest data provided by the International Marketing Services (IMS), consump-
tion of antihypertensive drugs in Spain has tripled in the last 15 years [2]. Moreover, once
established, antihypertensive drugs are usually given for the rest of the patient’s life and the
number of antihypertensive drugs available is increasing.
Breast cancer is the most common cancer among women in both developed and developing
countries. One in ten of all new cancers diagnosed worldwide each year is a cancer of the
female breast. It is also the leading cause of cancer death among women worldwide. More than
1.67 million cases are diagnosed and more than 522,000 patients die from it worldwide every
year [3].
The carcinogenic potential of antihypertensive drugs has been debated for nearly 50 years
[4]. Even since the nineties, contradictions between different studies have been observed. Some
studies showed that calcium channel blockers (CCBs) increase the overall risk of cancer, but no
significant association was found with breast cancer [5,6]. Other studies observed that CCBs
specifically increase the risk of breast cancer [7–9]; in contrast to others that did not find such
association [10–15]. The debate has recently been fueled again with new data reporting an
increased risk of breast cancer among women with a long history of use of antihypertensive
drugs compared with nonusers [16–19].
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The discrepant results and the high prevalence of antihypertensive medication in middle-
aged population justify carrying out new research in order to provide additional evidence
about the relationship with cancer development. The aim of the present study is to assess the
association between breast cancer and previous use of antihypertensive medication, taking into
account the class of antihypertensive drug and the duration of use, in a large population-based
case-control study conducted in Spain, the MCC-Spain study.
Materials and Methods
Ethics Statement
This study was approved by the corresponding ethics committee of each area (Comité ético de
investigación clínica de Asturias, Barcelona, Cantabria, Girona, Gipuzkoa, Huelva, León,
Madrid, Navarra and Valencia) and informed written consent was obtained from parents. The
MCC-Spain study also followed the Declaration of Helsinki and the Spanish Personal Data
Protection Act of 1999.
Study design and population
The Multi Case-Control (MCC-Spain) study has been described in detail [20]. Briefly, it is a
population-based case-control study of common tumors in Spain; the recruitment includes
incident cases of colorectal, breast, gastroesophageal and prostate cancer diagnosed between
September 1st, 2008 and December 31st, 2013. Henceforth, we will only refer to breast cancer
cases and their controls.
All cases of breast cancer included were incident and pathology confirmed, with no previous
diagnosis of breast cancer; they were aged between 20 and 85 years old, and resident within the
influence area of the hospital for at least 6 months prior to recruitment in 10 Spanish provinces
(Asturias, Barcelona, Cantabria, Girona, Gipuzkoa, Huelva, León, Madrid, Navarra and Valen-
cia). Controls with no prior history of breast cancer were selected from the general population
according to age and regional distribution of the cases included in the study. In this paper,
1736 cases of breast cancer in women and their 1895 frequency-matched controls were consid-
ered. Response rates were 71% for breast cancer and 72% for controls, with no differences in
the main socio-demographic variables among those who participated and those who refused to
participate.
Exposure data
Participants were interviewed face-to-face by trained interviewers, using a comprehensive epi-
demiological questionnaire that collected socio-demographic information, personal and family
history of cancer, anthropometric data, smoking habits, alcohol intake, occupation, physical
activity, water consumption, reproductive and medical history and medication use, family his-
tory, sun exposure, sleep habits, use of hygiene products and cosmetics, signs and symptoms.
Comprehensive dietary habits were obtained with the use of a validated food-frequency
questionnaire.
Participant’s weight was self-reported, as estimated one year before diagnosis for cases and
one year before the interview for controls. Accordingly, body mass index (BMI) was calculated
considering self-reported weight, referred to that date, and height. Total fat and vegetable
intakes were estimated from the questionnaire using local food composition tables. Similar esti-
mates provided total energy consumption. Physical activity was recorded for the longest occu-
pation and also considering recreational physical exercise.
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Detailed information was obtained on past medical conditions and the corresponding medi-
cations used. The age at onset, the dates of diagnosis or occurrence and the type of treatment
received for each condition was also registered.
Drug use assessment
Drug use was recorded by indication. For each drug, the brand name, dose and duration of
exposure were recorded to identify patients with regular drug consumption (“no” and “occa-
sionally” versus “yes”) and the duration of consumption.
The drugs were coded following the Anatomical Therapeutic Chemical Classification Sys-
tem (ATC codes) to define groups with similar mechanisms of action [WHOCC Homepage.
WHO Collaborating Centre for Drug Statistics Methodology].
All drugs indicated for the treatment of hypertensive diseases have been considered. The
ATC codes included in the present analysis are code C02 (Antihypertensive), C03 (Diuretics),
C04 (Peripheral vasodilators), C07 (Beta blocking agents), C08 (Calcium channel blockers)
and C09 (Agents acting on the renin-angiotensin system). Results will be presented for each
separate group and for specific antihypertensive drugs that had a prevalence of use over 1% in
controls.
Statistical Methods
Unconditional binomial logistic regression was used to assess the association between antihy-
pertensive drug use and breast cancer overall and stratifying for menopausal status and BMI
(<25/25 kg/m2). In order to study the relationship between antihypertensive drug use and
different breast cancer subtypes, we applied multinomial logistic regression models; multino-
mial logistic regression is useful when the outcome is categorical rather than dichotomic; for
instance, according to cancer stage, participants were classified in one out of three categories:
control / breast cancer stage I-II / breast cancer stage III-IV. Multinomial logistic regression
allows to estimate odds ratios for every category (i.e.: breast cancer stage I-II / breast cancer
stage III-IV) comparing with the reference category (i.e.: control) [21]. Statistical models were
adjusted for the following confounders: age, area of residence, education, BMI 1 year before,
active smoking, alcohol intake in the past, family history of breast cancer, age of menarche, age
at first full-term birth, parity, menopausal status and hormonal therapy.
Stratified models were developed according to menopausal status, BMI (<25/25 kg/m2),
clinical stage (I-II / III-IV), ductal (ductal/non ductal), invasive and immunohistochemistry
(hormone + receptors with Erbb2 negative, Erbb2 + receptors and triple negative receptors).
Results, which are reported only in strata with at least 5 cases or controls using antihyperten-
sive drugs are shown as odds ratios (OR) with 95% confidence intervals (CI). All reported p-
values are two-tailed. Statistical analysis was carried out using the package Stata 14/SE (Stata-
Corp, College Station, Tx, US).
Results
There were 1736 cases of breast cancer and 1895 controls. Table 1 describes the characteristics
of the women participating in this study. Compared with women in the control group, cases
were younger (56.4 Vs 59.0), used to smoke more (former smoker 26% cases, 21% controls)
though the proportion of current smokers was similar in both groups, had undergone fewer
deliveries (1.9 vs 2.0) and were more likely to have family history of breast cancer. The propor-
tion of premenopausal women was higher in cases than in controls (40% vs 33%). With respect
to food, cases consumed more kilocalories per day (1861 versus 1754). The grams per day of
red meat and alcohol were also higher in the group of women with breast cancer.
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Table 1. Main characteristics of cases and controls from the study population (only women have been included).
Baseline and clinical characteristics Category Breast Cancer
Cases
Population
Controls
p
N = 1736 N = 1895
Age, mean±sd 56.4±12.6 59.0±13.2 <0.001
Geographical area, n (%) Asturias 70 (4.0) 121 (6.4) <0.001
Barcelona 292 (16.8) 380 (20.1)
Cantabria 141 (8.1) 188 (9.9)
Girona 47 (2.7) 57 (3.0)
Gipuzkoa 226 (13.0) 255 (13.5)
Huelva 105 (6.1) 79 (4.2)
Leon 227 (13.1) 202 (10.7)
Madrid 341 (19.6) 365 (19.3)
Navarra 226 (13.0) 181 (9.6)
Valencia 61 (3.5) 67 (3.5)
Antihyperstensive drug
consumption, n (%)
Any antihypertensive therapy Yes 364(21.0) 406 (21.4) 0.651
No 1372(79.0) 1489(78.6)
Diuretics Yes 101(5.8) 111(5.8) 0.996
No 1635(94.2) 1798(94.2)
Calcium channel blockers Yes 61(3.5) 58(3.0) 0.42
No 1675(96.5) 1851(97.0
B-blockers Yes 76(4.4) 86(4.5) 0.852
No 1660(95.6) 1823(95.5)
Angitensin-converting-enzyme inhibitors
[ACEIs]
Yes 131(7.6) 160(8.4) 0.353
No 1605(92.5) 1749(91.6)
Angiotensin II receptor blockers [ARBs] Yes 129(7.4) 133(7.0) 0.588
No 1607(92.6) 1776(93.0
Family history of breast cancer, n (%) No 1288(74.2) 1614 (85.2) <0.001
First-degree relative 256 (14.8) 166 (8.8)
Second-degree
relative
174 (10.0) 105 (5.5)
Not Available 18 (0.8) 10(0.5)
Educational level, n (%) Less than primary
school
268 (15.4) 327 (17.3) 0.1
Primary school 565 (32.6) 581 (30.7)
Secondary school 573 (33.0) 585 (30.9)
University 330 (19.0) 402 (21.2)
Tobacco smoking, n (%) Never smoker 972 (56.0) 1141 (60.2) 0.002
Former smoker 450 (25.9) 397 (21.0)
Current smoker 314 (18.1) 357 (18.8)
Body Mass Index (kg/m2), n (%) <18.5 30 (1.7) 43 (2.3) 0.31
18.5–24.9 789 (45.5) 899 (47.4)
25.0–29.9 590 (34.0) 601 (31.7)
30 327 (18.8) 352 (18.6)
Energy intake (kcal/day), mean±sd 1861±644 1754±566 <0.001
Ethanol intake in the past (g/day), mean±sd 6.2±11.5 5.3±9.5 0.01
Red meat intake (g/day), mean±sd 26.9±20.2 25.2±19.9 0.01
Fruit intake (g/day), mean±sd 363±239 365±222 0.87
(Continued)
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Clinical-pathological characteristics of the breast cancers are reported in Table 2; ductal
cancer accounts for 74% cases; two out of three breast cancers were diagnosed at stage I or II;
more than 60% cancers were hormonal receptors, 14% were Erbb2 receptors + and only 9%
were triple negative breast cancers.
Table 1. (Continued)
Baseline and clinical characteristics Category Breast Cancer
Cases
Population
Controls
p
N = 1736 N = 1895
Vegetable intake (g/day), mean±sd 196±133 198±119 0.6
Number of full-term, mean±sd 1.9±1.5 2.0±1.6 0.03
Menopausal status, n (%) Premenopausal 702 (40.4) 628 (33.1) <0.001
Postmenopausal 1034 (59.6) 1267 (66.9)
Age at ﬁrst full-term, mean±sd* 26.5±5.0 26.5±4.7 0.82
Age at menarche, mean±sd 12.8±1.5 12.9±1.5 0.02
Age at menopause, mean±sd 48.8±5.4 48.5±5.3 0.18
Previous use of hormonal contraceptives, n (%) 789 (45.5) 868 (45.8) 0.83
*exclude nulliparous
doi:10.1371/journal.pone.0159672.t001
Table 2. Clinical and pathological characteristics of breast cancers.
Classiﬁcation N (%)
Pathology
Ductal 1289 (74.3)
Lobular 112 (6.5)
Papilar 22 (1.3)
Coloid 20 (1.2)
Tubular 12 (0.7)
Mixed 27 (1.6)
Other 35 (2.0)
Not Available 213 (12.3)
Clinical stage
0 115 (6.6)
I 604 (34.8)
II 495 (28.5)
III 182 (10.5)
IV 22 (1.3)
Not Available 318 (18.3)
Invasive
Invasive 1497 (86.2)
Non-invasive 166 (9.6)
Not Available 73 (4.2)
Inmunohistochemistry
Hormonal receptors 1117 (64.3)
Erbb2+ 255 (14.7)
Triple – 157 (9.04)
Not Available 207(11.9)
doi:10.1371/journal.pone.0159672.t002
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Antihypertensive drug consumption and risk of breast cancer according
to women’s characteristics
Table 3 and S1 Table–displaying the duration of consumption- show the relationship between
the use of antihypertensive drugs and the risk of breast cancer overall- and stratified by meno-
pausal status and BMI. No significant associations were found between breast cancer and any
antihypertensive drug for all women combined (Table 3). Users of any antihypertensive drug
doubled the risk of developing breast cancer in premenopausal women (OR = 2.15, 95%
CI = 1.17 to 3.96).
Table 3. Relationship between antihypertensive drug consumption and breast cancer according to women’s characteristics. Category reference
no antihypertensive treatment.
Population
Controls
Breast Cancer Cases if antihypertensive therapy
consumption
Exp / UnExp Exp / UnExp Adjusted
aOR
95%CI p-value
any antihypertensive therapy All women 367/1497 323/1372 1.16 0.94 1.43 0.17
Menopausal * Premenopausal 27/596 46/654 2.15 1.17 3.96 0.014
postmenopausal 335/893 277/718 1.09 0.86 1.37 0.468
BMI <25 120/809 74/742 1.04 0.71 1.54 0.838
25 247/688 249/630 1.19 0.92 1.54 0.179
Diuretics All women 104/1798 91/1635 0.98 0.7 1.39 0.929
Menopausal * Premenopausal 8/619 9/692 1.26 0.41 3.93 0.687
postmenopausal 95/1165 82/943 1 0.69 1.45 0.991
BMI <25 30/911 15/803 0.66 0.3 1.43 0.289
25 74/887 76/832 1.08 0.73 1.59 0.713
Calcium Channel Blockers All women 52/1851 53/1675 1.56 0.98 2.48 0.063
Menopausal * Premenopausal 3/624 3/699 0.51 0.05 5.15 0.567
postmenopausal 48/1213 50/976 1.72 1.05 2.8 0.03
BMI <25 19/921 10/808 0.89 0.34 2.3 0.81
25 33/930 43/867 2.05 1.16 3.63 0.013
B- blockers All women 78/1823 63/1660 1.11 0.75 1.63 0.614
Menopausal * Premenopausal 9/619 7/695 1.1 0.35 3.42 0.869
postmenopausal 67/1191 56/965 1.15 0.75 1.75 0.515
BMI <25 27/911 16/803 1.3 0.64 2.65 0.468
25 51/912 47/857 1 0.62 1.61 0.99
Angiotensin-converting-enzyme inhibitors
[ACEIs]
All women 136/1749 116/1605 1.02 0.75 1.38 0.918
Menopausal * Premenopausal 8/615 14/687 1.61 0.6 4.34 0.346
postmenopausal 125/1122 102/918 1 0.72 1.38 0.977
BMI <25 51/887 23/795 0.65 0.35 1.2 0.167
25 85/862 93/810 1.17 0.81 1.69 0.406
Angiotensin II receptor blockers [ARBs] All women 124/1776 118/1607 1.19 0.87 1.62 0.286
Menopausal * Premenopausal 8/620 18/683 4.27 1.32 13.84 0.015
postmenopausal 115/1144 100/924 1.05 0.75 1.46 0.788
Abbreviations: CI, Conﬁdence interval; OR, odds ratio
aOR adjusted for the matching factors age, area of resident, education, body mass index, active smoking, alcohol intake, family history of breast cancer, age
of menarche, age ﬁrst full-term births, number of full-term births, menopausal status, hormonal therapy.
*OR adjusted for the matching factors age, area of resident, education, body mass index, active smoking, alcohol intake, family history of breast cancer,
age of menarche, age ﬁrst full-term births, number of full-term births, hormonal therapy
doi:10.1371/journal.pone.0159672.t003
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When examining specific classes of antihypertensive drugs, the use of CCBs was associated
with a 72% increased risk of breast cancer in the postmenopausal group (OR = 1.72, 95%
CI = 1.05 to 2.80) and twice the risk in women with BMI 25 (OR = 2.05, 95% CI = 1.16 to
3.63); there is moderate confirmation of both associations in women taking CCBs for 5 years
or more. Angiotensin II receptor blockers (ARB) were the only group associated with an
increased risk of breast cancer in premenopausal women (OR = 4.27, 95% CI = 1.32 to 13.84),
but not in postmenopausal women (p for ARB–menopausal status interaction = 0.03). The use
of diuretics, beta blockers and angiotensin converting enzyme inhibitors (ACEI) was not asso-
ciated with breast cancer risk in any women or in different strata.
Antihypertensive drug consumption and risk of breast cancer according
to tumor characteristics
Results of the association between the use of antihypertensive drugs and incident breast cancer
according to tumor characteristics are shown in Table 4 and in S2 Table for the duration of
consumption. Altogether, the use of antihypertensive drugs was associated with a higher risk of
triple negative breast cancer (OR = 2.21, 95% CI = 1.37 to 3.56; p for heterogeneity = 0.03); this
result was consistently reproduced in women undergoing antihypertensive treatment for more
or less than 5 years (S2 Table). Antihypertensive drugs were also associated with more aggres-
sive or worse prognosis cancer: taking antihypertensive drugs increased the risk of developing
a tumor in clinical stage III-IV (OR = 1.62; 95% CI = 1.04 to 2.52; p for antihypertensive drug–
clinical stage heterogeneity = 0.22), non-ductal tumor (OR = 1.49; 95% CI = 1.00 to 2.24; p for
antihypertensive drug–ductal cancer interaction = 0.32), invasive cancer (OR = 1.26, 95%
CI = 1.01 to 1.57; p for antihypertensive drug–invasive cancer interaction = 0.02), although
results taking into account the treatment length did not reveal a risk pattern consistent with
higher risk in women taking antihypertensive drugs for more than 5 years (S2 Table).
Looking at specific classes of antihypertensive drugs, CCBs were even more strongly associ-
ated with more aggressive tumors, multiplying by 2.7 the risk of tumors in stage III-IV
(OR = 2.70, 95% CI = 1.23 to 5.95), non-ductal cancers (OR = 2.63, 95% CI = 1.27 to 5.43), and
Erbb2+ cancer (OR = 2.52, 95% CI: 1.18 to 5.37). CCBs were also associated with invasive
tumors (OR = 1.67, 95% CI = 1.04 to 2.70). Similar results were found in women taking CCBs
for at least five years.
The use of diuretics, beta blockers, ACEIs or ARBs was not associated with increased risk
for specific tumor characteristics.
Discussion
In this population-based case-control study the use of antihypertensive medications as a global
group was associated with higher risk of invasive breast cancer, and this risk appears to be con-
fined to triple negative breast cancer and concentrated in premenopausal women. Our results
were similar to those found in a large prospective study, the California Teachers Study (CTS)
with 133,479 women [16]. In contrast, another recent study, the Nurses’ Health Study (NHS)
with 210,641 participants [22], did not find this association. On the other hand, we found that
CCB consumption increased the odds of breast cancer in postmenopausal women, women
with BMI over 25 kg/m2, cancer in stages III-IV, non-ductal cancer and Erbb2+ cancer. Previ-
ous results on CCB-breast cancer relationship have been contradictory; Fitzpatrick et al, in a
study limited to women aged 65 years or more, found an elevated risk of breast cancer associ-
ated with CCB usage [7]; Li et al (2003) reported an increase in breast cancer risk in former
users of CCBs, but they failed to find any trend of increasing risk associated with longer dura-
tion [8]; Li et al (2013) found that CCB usage was associated with both ductal and non-ductal
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Table 4. Relationship between antihypertensive drug consumption and breast cancer according to tumor characteristic. Category reference: no
antihypertensive treatment.
Population Breast Cancer Cases if antihypertensive
therapy consumption
Controls
Exp / UnExp Exp /
UnExp
Adjusted
aOR
95%
CI
p-
value
any antihypertensive therapy Clinical Stage I-II 367/1497 208/872 1.22 0.96 1.55 0.105
III-IV 367/1497 47/154 1.62 1.04 2.52 0.032
ductal Ductal 367/1497 245/1015 1.21 0.96 1.53 0.103
Non ductal 367/1497 50/177 1.49 1 2.24 0.052
Invasive In situ 367/1497 21/143 0.63 0.35 1.13 0.123
Invasive 367/1497 289/1172 1.26 1.01 1.57 0.038
Inmunohistochemistry hormone +receptors 367/1497 210/884 1.13 0.89 1.44 0.313
Erbb2+ 367/1497 45/205 1.13 0.74 1.73 0.563
receptors
triple negative
receptors
367/1497 41/111 2.21 1.37 3.56 0.001
Diuretics Clinical Stage I-II 104/1798 55/1039 0.9 0.6 1.34 0.598
III-IV 104/1798 11/193 1 0.48 2.09 0.994
ductal Ductal 104/1798 72/1209 1.03 0.71 1.49 0.89
Non ductal 104/1798 10/223 0.78 0.37 1.63 0.507
Invasive In situ 104/1798 5/161 0.68 0.24 1.95 0.473
Invasive 104/1798 82/1406 1.01 0.71 1.45 0.939
Inmunohistochemistry hormone +receptors 104/1798 56/1054 0.9 0.6 1.34 0.601
Erbb2+ 104/1798 14/240 1.05 0.54 2.07 0.881
receptors
triple negative
receptors
104/1798 13/144 1.54 0.77 3.08 0.224
Calcium Channel Blockers Clinical Stage I-II 52/1851 29/1065 1.34 0.78 2.3 0.287
III-IV 52/1851 11/193 2.7 1.23 5.95 0.014
ductal Ductal 52/1851 38/1248 1.5 0.9 2.51 0.12
Non ductal 52/1851 12/218 2.63 1.27 5.43 0.009
Invasive In situ 52/1851 3/163 - - - -
Invasive 52/1851 49/1441 1.67 1.04 2.7 0.035
Inmunohistochemistry hormone +receptors 52/1851 33/1080 1.46 0.86 2.47 0.164
Erbb2+ 52/1851 12/242 2.52 1.18 5.37 0.017
receptors
triple negative
receptors
52/1851 4/152 - - - .
B- blockers Clinical Stage I-II 78/1823 40/1054 1.1 0.71 1.72 0.658
III-IV 78/1823 9/194 1.23 0.54 2.8 0.626
ductal Ductal 78/1823 48/1229 1.16 0.76 1.77 0.5
Non ductal 78/1823 8/225 1.04 0.48 2.26 0.921
Invasive In situ 78/1823 4/162 - - - .
Invasive 78/1823 55/1429 1.17 0.78 1.75 0.455
Inmunohistochemistry hormone +receptors 78/1823 38/1073 0.96 0.61 1.52 0.876
Erbb2+receptors 78/1823 6/246 0.79 0.33 1.9 0.602
triple negative
receptors
78/1823 9/146 2.04 0.95 4.38 0.068
(Continued)
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breast cancer, but only if duration of CCB consumption was longer than 10 years [17]; while a
small but statistically significant effect of CCBs on breast cancer incidence was also reported by
Leung (2015)[18]. Negative results have been published, however, in other studies [10–
15,23,24].
CCBs may increase the risk of cancer by changing intracellular calcium levels, which could
affect the process of programmed cell death, not enabling the destruction of damaged cells to
prevent the development of diseases such as cancer, resulting in indiscriminate replication of
an impaired cell [25]. Calcium plays a regulatory role in apoptosis acting through various sig-
naling pathways such as the activation of the caspase [26–28] or the induction of endonuclease
activity [29]. In addition, calcium is involved in triggering cell death by mitochondrial permea-
bilization [30] and promoting phagocytosis by phosphatidylserine exposure on the cell surface
by apoptosis [31].
On the other hand, nifedipine–a CCB- has been found to increase proliferation and migra-
tion of breast cancer cells, which could be responsible for the association between CCBs and
late stage cancers. This nifedipine effect–which is not shared by other CCBs such as verapamil-
seems to be produced via the Erk pathway activation and is independent of the calcium chan-
nel-blocking effect [32].
Table 4. (Continued)
Population Breast Cancer Cases if antihypertensive
therapy consumption
Controls
Exp / UnExp Exp /
UnExp
Adjusted
aOR
95%
CI
p-
value
Angiotensin-converting-enzyme
inhibitors [ACEIs]
Clinical Stage I-II 136/1749 77/1015 1.09 0.77 1.53 0.634
III-IV 136/1749 14/189 1.01 0.51 1.98 0.982
ductal Ductal 136/1749 83/1196 0.95 0.67 1.33 0.754
Non ductal 136/1749 22/209 1.78 1.06 2.98 0.029
Invasive In situ 136/1749 9/157 0.86 0.38 1.95 0.725
Invasive 136/1749 104/1380 1.1 0.8 1.51 0.554
Inmunohistochemistry hormone +receptors 136/1749 85/1025 1.19 0.85 1.67 0.321
Erbb2+receptors 136/1749 12/242 0.7 0.35 1.39 0.303
triple negative
receptors
136/1749 14/139 1.43 0.73 2.79 0.293
Angiotensin II receptor blockers [ARBs] Clinical Stage I-II 124/1776 76/1019 1.34 0.95 1.9 0.099
III-IV 124/1776 19/184 1.75 0.97 3.18 0.065
ductal Ductal 124/1776 91/1189 1.28 0.91 1.79 0.152
Non ductal 124/1776 16/218 1.22 0.67 2.21 0.514
Invasive In situ 124/1776 9/155 0.71 0.29 1.73 0.452
Invasive 124/1776 104/1384 1.24 0.9 1.71 0.197
Inmunohistochemistry hormone +receptors 124/1776 74/1039 1.11 0.78 1.58 0.568
Erbb2+ 124/1776 19/234 1.45 0.81 2.61 0.214
receptors
triple negative
receptors
124/1776 14/142 1.74 0.88 3.41 0.109
Abbreviations: CI, Conﬁdence interval; OR, odds ratio
aOR adjusted for the matching factors age, area of resident, education, body mass index, active smoking, alcohol intake, family history of breast cancer, age
of menarche, age ﬁrst full-term births, number of full-term births, menopausal status, hormonal therapy.
doi:10.1371/journal.pone.0159672.t004
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Other antihypertensive drugs
ARBs were the only antihypertensive group associated with an increased risk of breast cancer
in premenopausal women in our results; using ARBs before menopause was, however, scarce;
therefore, when stratifying by length of consumption the results were non-significant, although
the odds ratios scaled from 3.48 for less than 5 year users to 6.64 for 5 or more year users. We
have not found other papers analyzing the relationship between ARBs and breast cancer in pre-
menopausal women; this together with the small number of premenopausal women taking
ARBs make the interpretation of this result highly speculative. Bhashkaran et al (2012) found
an increased risk of breast cancer associated with short-term exposure to ARBs; they suggested
that such an association could not be causal but the result of confounding by indication:
according to them, some early symptoms of breast cancer could induce ARBs to be indicated
instead of ACEIs in hypertensive patients, leading, therefore, to a spurious ARB–breast cancer
association [33]. We have no data for exploring such an explanation in our study.
Differences in study design and population characteristics may explain the conflicting
results reported on the antihypertensive drugs–breast cancer association. Inferring is difficult
because of the small sample size in some studies, differences in the populations evaluated and
designs (cohort of patients, general population cohorts and case-control studies). In many
cases, randomized trials cannot identify long-term adverse effects of medication because they
are usually conducted for relatively shorter periods (i.e.: 5 years or less) [34]. Subsequent long-
term monitoring of drugs through observational studies may overcome this limitation and
provide new information in this regard. Some observational studies have analyzed the antihy-
pertensive drugs-breast cancer relationship by working with administrative data, which were
not designed for this objective. That kind of design does not allow an adequate adjustment for
confounding factors. Although some studies linked the use of CCB and cancer in the 90s, anti-
hypertensive consumption was different to today’s. Nowadays, more therapeutic options are
available; the use of antihypertensive drugs is characterized by the appearance of new fixed-
dose combinations of two active antihypertensive drugs and by the introduction of new drug
treatments belonging to the group of ARBs, beta blockers or CCBs [1].
The present study has some limitations. First, recall bias should be considered as in any
case-control study. Drug consumption was obtained using a standardized questionnaire in
face-to-face interviews where examiners were blinded to the case-control status. If a non-differ-
ential recall bias was produced, then the odds ratios should be downward biased and the posi-
tive associations we have found for CCB, ARBs or ACEIs would actually be even stronger than
reported here. If a differential recall bias were responsible for these associations, breast cancer
cases would also have over-declared (or controls under-declared) their consumption of other
hypertensive drugs; however, no association has been found between breast cancer and diuret-
ics or beta-blockers, which makes a differential recall bias less probable. Second, some strata in
our study have small numbers of exposed cases or controls; this could produce unstable esti-
mates. This limitation should be especially considered regarding ARBs, as their relationship
with breast cancer is confined to premenopausal women, a relatively small subgroup whose
exposure to hypertensive drugs could not be too long. Third, antihypertensive consumption
was reported by indication; therefore, most people taking antihypertensive drugs have hyper-
tension. Thus, we cannot distinguish using antihypertensive drugs from having hypertension.
Lastly, many comparisons have been made, raising the probability of finding some spurious
results However, the consistency of some results in different subgroups, such as those for
CCBs, supports the existence of a real excess risk associated with their use.
In summary, we report that consumption of antihypertensive medications -as a global
group- was associated with an increased odds of breast cancer in premenopausal women, and
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the use of CCBs in particular was associated with an increased odds of breast cancer in post-
menopausal women and those with BMI higher than 25 Kg/m2. As people with hypertension
are expected to take antihypertensive drugs for many years, their relative effect on breast cancer
should be taken into account when choosing the antihypertensive to be prescribed.
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